CRISPR Therapeutics AG (CRSP)

Recent filings

CRISPR Therapeutics AG Just Filed Its Quarterly Report: 10. Net Loss Per Sha... - April 27, 2021

Crispr Therapeutics Provides Business Update And Reports First Quarter 2021 Financial Results - April 27, 2021

Vertex Pharmaceuticals And Crispr Therapeutics Amend Collaboration For Development, Manufacturing And Commercialization Of Ctx001™ In Sickle Cell Disease And Beta Thalassemia - April 20, 2021

Other preliminary proxy statements - April 5, 2021

CRISPR Therapeutics AG's CBO & COO just disposed of 12,000 shares - March 25, 2021

CRISPR Therapeutics AG director just disposed of 30,374 shares - March 24, 2021

CRISPR Therapeutics AG's Chief Financial Officer just picked up 1,481 shares - March 12, 2021

CRISPR Therapeutics AG's CBO & COO just picked up 16,334 shares - March 12, 2021

Executive VP of CRISPR Therapeutics AG just picked up 2,442 shares - March 12, 2021

CRISPR Therapeutics AG's General Counsel and Secretary just picked up 1,480 shares - March 12, 2021

CRISPR Therapeutics AG's Chief Executive Officer just picked up 6,307 shares - March 12, 2021

CRISPR Therapeutics AG's CBO & COO just picked up 2,442 shares - March 12, 2021

Executive VP of CRISPR Therapeutics AG just picked up 1,748 shares - March 9, 2021

CRISPR Therapeutics AG director just disposed of 264,884 shares - March 3, 2021

CRISPR Therapeutics AG's Chief Executive Officer just disposed of 798 shares - March 3, 2021

CRISPR Therapeutics AG director just disposed of 1,159,869 shares - Feb. 23, 2021

Capital International Investors just provided an update on share ownership of CRISPR Therapeutics AG - Feb. 16, 2021

Versant Venture Management, LLC just provided an update on activist position in CRISPR Therapeutics AG - Feb. 16, 2021

Crispr Therapeutics Provides Business Update And Reports Fourth Quarter And Full Year 2020 Financial Results - Feb. 16, 2021

ARK Investment Management LLC just provided an update on share ownership of CRISPR Therapeutics AG - Feb. 16, 2021

Nikko Asset Management Americas, Inc. just provided an update on share ownership of CRISPR Therapeutics AG - Feb. 11, 2021

Nikko Asset Management Co., Ltd. just provided an update on share ownership of CRISPR Therapeutics AG - Feb. 5, 2021

CRISPR Therapeutics AG's Chief Executive Officer just cashed-in 20,000 options - Jan. 20, 2021

CRISPR Therapeutics AG's General Counsel and Secretary just cashed-in 27,500 options - Jan. 20, 2021

CRISPR Therapeutics AG's CBO & COO just picked up 10 shares - Jan. 20, 2021

CRISPR Therapeutics AG just filed a prospectus, suggesting it plans to soon issue some securities - Jan. 15, 2021

As previously - Jan. 15, 2021

CRISPR Therapeutics AG's CBO & COO just disposed of 9,392 shares - Jan. 4, 2021

CRISPR Therapeutics AG's Chief Executive Officer just picked up 13,800 shares - Dec. 30, 2020

Executive VP of CRISPR Therapeutics AG just cashed-in 23,551 options - Dec. 22, 2020

CRISPR Therapeutics AG director just disposed of 15,000 shares - Dec. 18, 2020

CRISPR Therapeutics AG director just disposed of 33,000 shares - Dec. 17, 2020

CRISPR Therapeutics AG director just disposed of 33,000 shares - Dec. 14, 2020

CRISPR Therapeutics AG just filed a prospectus, suggesting it plans to soon issue some securities - Dec. 11, 2020

As previously - Dec. 11, 2020

Statement of changes in beneficial ownership of securities - Dec. 11, 2020

CRISPR Therapeutics AG's General Counsel and Secretary just picked up 22,026 shares - Dec. 10, 2020

CRISPR Therapeutics AG director just disposed of 171,004 shares - Dec. 9, 2020

Crispr Therapeutics And Vertex Present New Data For Investigational Crispr/Cas9 Gene-Editing Therapy, Ctx001 - Dec. 7, 2020

Sorry, no schedule available for this company

CRISPR Therapeutics to Participate in Upcoming Investor Conferences - April 29, 2021

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results - April 27, 2021

Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency to CTX001™ for Transfusion-Dependent Beta Thalassemia - April 26, 2021

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia - April 20, 2021

CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function - April 10, 2021

CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting - March 10, 2021

CRISPR Therapeutics to Participate in Upcoming Investor Conferences - March 3, 2021

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - Feb. 16, 2021

CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day - Feb. 5, 2021

CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer - Feb. 1, 2021

CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine - Dec. 5, 2020

CRISPR Therapeutics and Vertex to Host Investor Webcast to Review Data Presented at the 62nd American Society of Hematology Annual (ASH) Meeting and Exposition for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ in Sickle Cell Disease and Beta Thalassemia - Dec. 1, 2020

CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference - Nov. 24, 2020

CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference - Nov. 16, 2020

CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition - Nov. 4, 2020

CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies - Oct. 21, 2020

CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry - Oct. 7, 2020

CRISPR Therapeutics to Participate in Upcoming Investor Conferences - Sept. 29, 2020

CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference - Sept. 3, 2020

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results - July 27, 2020

 


Feedback